Clinical Trials · NCT06534411
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,023
- Start date
- Nov 2024
- Locations
- 163 sites, 14 countries
- Primary endpoint
- Change in Glycated Haemoglobin (HbA1c)